DOP2010000072A - Activadores de guanilato ciclasas solubles - Google Patents
Activadores de guanilato ciclasas solublesInfo
- Publication number
- DOP2010000072A DOP2010000072A DO2010000072A DO2010000072A DOP2010000072A DO P2010000072 A DOP2010000072 A DO P2010000072A DO 2010000072 A DO2010000072 A DO 2010000072A DO 2010000072 A DO2010000072 A DO 2010000072A DO P2010000072 A DOP2010000072 A DO P2010000072A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- guanilate
- activators
- cycling
- soluble
- dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto que tiene la estructura util para el tratamiento o prevencion de enfermedades cardiovasculares, disfuncion endotelial, disfuncion diastolica, aterosclerosis, hipertension, angina de pecho, trombosis, reestenosis, infarto de miocardio, apoplejias, insuficiencia cardiaca, hipertonia pulmonar, disfuncion erectil, asma bronquial, insuficiencia renal cronica, diabetes, o cirrosis del higado en un paciente humano o animal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96782707P | 2007-09-06 | 2007-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2010000072A true DOP2010000072A (es) | 2010-06-30 |
Family
ID=40070857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000072A DOP2010000072A (es) | 2007-09-06 | 2010-03-05 | Activadores de guanilato ciclasas solubles |
Country Status (18)
Country | Link |
---|---|
US (2) | US8455638B2 (es) |
EP (1) | EP2197551B1 (es) |
JP (1) | JP5298129B2 (es) |
KR (1) | KR20100059952A (es) |
CN (1) | CN101939053A (es) |
AU (1) | AU2008296974B2 (es) |
BR (1) | BRPI0816382A2 (es) |
CA (1) | CA2698332C (es) |
CO (1) | CO6260089A2 (es) |
CR (1) | CR11326A (es) |
DO (1) | DOP2010000072A (es) |
EA (1) | EA201070339A1 (es) |
EC (1) | ECSP10010017A (es) |
MA (1) | MA31749B1 (es) |
MX (1) | MX2010002608A (es) |
NI (1) | NI201000034A (es) |
TN (1) | TN2010000106A1 (es) |
WO (1) | WO2009032249A1 (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2720343A1 (en) | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
AU2010218224B2 (en) * | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
HUE028008T2 (en) * | 2010-02-05 | 2016-11-28 | Adverio Pharma Gmbh | sGC stimulators or sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis |
WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
CA2955143C (en) | 2010-05-26 | 2020-02-11 | Claudia Hirth-Dietrich | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
DK2588465T3 (en) | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2766360B1 (en) | 2011-08-12 | 2017-07-12 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
RU2640416C2 (ru) | 2012-04-16 | 2018-01-09 | Тоа Эйо Лтд. | Бициклическое соединение |
CA2879456A1 (en) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralincarboxylic acids and use thereof |
PT2875003T (pt) | 2012-07-20 | 2017-02-16 | Bayer Pharma AG | Novos ácidos 5-amino-tetra-hidroquinolina-2-carboxílicos e sua utilização |
RS59394B1 (sr) * | 2012-09-07 | 2019-11-29 | Boehringer Ingelheim Int | Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze |
MX361208B (es) | 2013-03-15 | 2018-11-30 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
AU2014316690B2 (en) * | 2013-09-05 | 2017-08-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
RU2673245C2 (ru) | 2013-10-15 | 2018-11-23 | Тоа Эйо Лтд. | Производные 4-аминометилбензойной кислоты |
US20160256460A1 (en) | 2013-11-01 | 2016-09-08 | Bergen Teknologioverføring As | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome |
EP3079701B1 (en) | 2013-12-11 | 2021-08-11 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EA032028B1 (ru) | 2013-12-11 | 2019-03-29 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ рГЦ |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625586A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
WO2016014463A1 (en) | 2014-07-22 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
CN105980373A (zh) * | 2014-09-05 | 2016-09-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 新的可溶性鸟苷酸环化酶活化剂及它们的用途 |
CA2959757A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
CA2961489A1 (en) | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
EA201792346A1 (ru) | 2015-05-06 | 2018-05-31 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) |
WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
MA52309A (fr) | 2015-06-15 | 2021-02-24 | Astex Therapeutics Ltd | Régulateurs de nrf2 |
EP3766878B1 (en) | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
WO2017060855A1 (en) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
WO2017060854A1 (en) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
US10316020B2 (en) | 2015-12-18 | 2019-06-11 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
US10696698B2 (en) | 2016-01-28 | 2020-06-30 | ACatechol, Inc. | Surface primer compositions and methods of use |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
WO2017200857A1 (en) | 2016-05-18 | 2017-11-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
ES2894251T3 (es) * | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
MA45588A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Formes solides d'un stimulateur de la gcs |
EP3481837B1 (en) | 2016-07-07 | 2023-12-06 | Cyclerion Therapeutics, Inc. | Phosphorus prodrugs of sgc stimulators |
CR20220309A (es) | 2016-09-02 | 2022-09-16 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
JP7237823B2 (ja) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Sgcアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ |
MA46755A (fr) | 2016-11-08 | 2021-06-02 | Cyclerion Therapeutics Inc | Stimulateurs de sgc |
SG10202104865UA (en) | 2016-11-08 | 2021-06-29 | Cyclerion Therapeutics Inc | Treatment of cns diseases with sgc stimulators |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
US11591289B2 (en) | 2017-02-24 | 2023-02-28 | Xeniopro GmbH | Aromatic compounds |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
JP7337067B2 (ja) | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
PE20210124A1 (es) | 2018-03-07 | 2021-01-19 | Cyclerion Therapeutics Inc | FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
CN113166157A (zh) | 2018-11-28 | 2021-07-23 | 托帕杜制药公司 | 新型双作用模式可溶性鸟苷酸环化酶活化剂和磷酸二酯酶抑制剂及其用途 |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
CA3170507A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
CA3170508A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
US20230128032A1 (en) | 2020-03-31 | 2023-04-27 | Curtails Llc | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
BR112023021851A2 (pt) | 2021-04-20 | 2024-02-06 | Tisento Therapeutics Inc | Estimulantes de sgc |
EP4326268A1 (en) | 2021-04-20 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
WO2024086179A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
WO2024086182A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4011361A1 (de) | 1990-04-07 | 1991-10-10 | Bayer Ag | 2-aryl-6-hetarylpyridin-derivate |
DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
AU8129998A (en) * | 1998-07-13 | 2000-02-01 | Hyogo Trading Co., Ltd. | Transfer coating material and method for transfer coating mirror surface |
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
US20010044445A1 (en) * | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
JP2003513064A (ja) * | 1999-11-05 | 2003-04-08 | ユニバーシティ カレッジ ロンドン | 可溶性グアニル酸シクラーゼのアクチベーター |
EP1373222A2 (de) | 2001-03-15 | 2004-01-02 | Basf Aktiengesellschaft | 5-phenylpyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von schadpilzen |
DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
AU2003294275A1 (en) | 2002-11-21 | 2004-06-18 | New York Blood Center | Compounds for inhibition of hiv infection by blocking hiv entry |
JP2006522130A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
KR20080016648A (ko) | 2005-06-15 | 2008-02-21 | 화이자 리미티드 | 기생충 방제용 치환된 아릴피라졸 |
WO2006134459A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles |
BRPI0612287A8 (pt) * | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
ES2430821T3 (es) | 2006-10-10 | 2013-11-21 | Amgen Inc. | Compuestos de N-arilpirazol para usar contra la diabetes |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
AR069517A1 (es) | 2007-12-03 | 2010-01-27 | Smithkline Beecham Corp | Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc |
CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
AU2010218224B2 (en) * | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
-
2008
- 2008-09-02 BR BRPI0816382-0A2A patent/BRPI0816382A2/pt not_active IP Right Cessation
- 2008-09-02 KR KR1020107007505A patent/KR20100059952A/ko not_active Application Discontinuation
- 2008-09-02 MX MX2010002608A patent/MX2010002608A/es not_active Application Discontinuation
- 2008-09-02 US US12/674,795 patent/US8455638B2/en active Active
- 2008-09-02 AU AU2008296974A patent/AU2008296974B2/en not_active Ceased
- 2008-09-02 CN CN2008801148009A patent/CN101939053A/zh active Pending
- 2008-09-02 EA EA201070339A patent/EA201070339A1/ru unknown
- 2008-09-02 JP JP2010524020A patent/JP5298129B2/ja not_active Expired - Fee Related
- 2008-09-02 CA CA2698332A patent/CA2698332C/en not_active Expired - Fee Related
- 2008-09-02 EP EP08829497.0A patent/EP2197551B1/en active Active
- 2008-09-02 WO PCT/US2008/010321 patent/WO2009032249A1/en active Application Filing
-
2009
- 2009-04-27 US US12/430,420 patent/US20090209556A1/en not_active Abandoned
-
2010
- 2010-03-04 NI NI201000034A patent/NI201000034A/es unknown
- 2010-03-05 DO DO2010000072A patent/DOP2010000072A/es unknown
- 2010-03-05 TN TNP2010000106A patent/TN2010000106A1/fr unknown
- 2010-03-05 EC EC2010010017A patent/ECSP10010017A/es unknown
- 2010-03-15 CO CO10030403A patent/CO6260089A2/es not_active Application Discontinuation
- 2010-03-22 CR CR11326A patent/CR11326A/es not_active Application Discontinuation
- 2010-04-01 MA MA32727A patent/MA31749B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008296974A1 (en) | 2009-03-12 |
CA2698332A1 (en) | 2009-03-12 |
US20090209556A1 (en) | 2009-08-20 |
TN2010000106A1 (en) | 2011-09-26 |
KR20100059952A (ko) | 2010-06-04 |
EP2197551A1 (en) | 2010-06-23 |
ECSP10010017A (es) | 2010-07-30 |
NI201000034A (es) | 2010-08-23 |
EP2197551B1 (en) | 2016-12-28 |
CN101939053A (zh) | 2011-01-05 |
MA31749B1 (fr) | 2010-10-01 |
CA2698332C (en) | 2012-08-21 |
JP5298129B2 (ja) | 2013-09-25 |
CR11326A (es) | 2010-06-23 |
AU2008296974B2 (en) | 2013-10-10 |
WO2009032249A1 (en) | 2009-03-12 |
EA201070339A1 (ru) | 2010-10-29 |
CO6260089A2 (es) | 2011-03-22 |
MX2010002608A (es) | 2010-06-01 |
BRPI0816382A2 (pt) | 2015-02-24 |
US8455638B2 (en) | 2013-06-04 |
JP2010538065A (ja) | 2010-12-09 |
US20110118282A1 (en) | 2011-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11326A (es) | Activadores de guanilato ciclasas solubles | |
CO6430463A2 (es) | Activadores de guanilato ciclasa solubles | |
CL2008001201A1 (es) | Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca. | |
CL2012001298A1 (es) | Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras. | |
CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
CL2014001779A1 (es) | Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
CL2013001600A1 (es) | Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras. | |
CL2008002006A1 (es) | Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular. | |
CY2016017I2 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
CL2007003874A1 (es) | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio | |
EA201100306A1 (ru) | Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1 | |
DK1865976T3 (da) | Anvendelse af natriuretiske peptider til behandling af hjertesvigt | |
CL2008002478A1 (es) | Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras. | |
DE602006005389D1 (de) | Enzymatische produktion von persäuren unter verwen | |
CL2012002069A1 (es) | Compuestos derivados de ácido 3-heteroarilamino-propiónico sustituido;inhibidor de proteasa catepsina a; proceso de preparacion; composicion farmaceutica; y su uso para tratar insuficiencia cardiaca, infarto de miocardio, hipertension, artritis reumatoide, asma insuficiencia renal, fobrosis quistica, bronquitis cronica, trombosis, dolor. | |
DOP2010000075A (es) | Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo | |
CY1112270T1 (el) | Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης | |
ATE443463T1 (de) | Regal-fachboden | |
CR11397A (es) | Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo | |
BRPI0923067A2 (pt) | "anodo capacitor". | |
BR112013009389A2 (pt) | composto heterocíclico derivado de diazênio-diolato, e , composição farmacêutica | |
EA200702201A1 (ru) | Рофлумиласт для лечения лёгочной гипертензии | |
DE602006020204D1 (de) | Elektronenquelle, ihre Herstellungsmethode, Elektronenemmisionsapparat und Anzeigetafel mit der Elektronenquelle | |
CL2012002341A1 (es) | Composición farmacéutica sólida oral que comprende ramipril y besilato de amlodipino; procedimiento de preparación; uso en el tratamiento de hipertensión arterial y prevención de infarto de miocardio, trastornos cerebrovasculares y cardíacos e insuficiencia renal. | |
EA200802436A1 (ru) | Профиль из листового металла для сухого способа строительства |